Figure 5.

The clinical efficacy of Signature-1 validated in three published cohorts. (A) Correlations between Signature-1 score (used “ssgsea” method in GSVA R package) and durable clinical benefit in Prat et al., Riaz et al., and Liu et al. (B, C) Correlations between the fraction of CD8+ T cells, CD4+ T cells, Tregs, and PD-L1 expression level and Signature-1 in pre-therapy (baseline) and on-therapy samples. (D) Dynamic change of the fraction of CD8+ T cells, CD4+ T cells, Tregs, and PD-L1 expression level between pre-therapy (baseline) and on-therapy samples in Signature-1 upregulated and downregulated groups. Upregulated: Log2 fold change of Signature-1 score in on-therapy and pre-therapy samples > 0; Downregulated: Log2 fold change of Signature-1 score in on-therapy and pre-therapy samples < 0.